Newsroom
GEN Announces First Patient Dosed in Phase II Clinical Trial of SUL-238 in Parkinson’s Disease
Proof-of-concept SHEPHERD study will assess SUL-238’s effects on mitochondrial function in patients with Parkinson’s disease Ankara, Türkiye, June 08, 2026 – GEN Pharmaceuticals (GENIL.IS), Türkiye’s leading specialty pharmaceutical company,...
GEN Receives Ethical Approval to Launch Phase II Clinical Trial for SUL-238 Targeting Mitochondrial Dysfunction in Patients with Parkinson’s Disease
ANKARA, Türkiye, March 16, 2026 - GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, announced today that it has received approval in the Netherlands from the BEBO Foundation for the Assessment of Ethics of...
GEN and Sulfateq shared the positive results from the multiple-dose Phase 1 study of SUL-238 at CTAD 2025
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases. Ankara, Türkiye, December 02, 2025 – GEN Pharmaceuticals (GENIL.IS), Türkiye’s leading specialty pharmaceutical...
SUL-compounds: first-in-class mitochondria-targeted medicines as potential treatment for cardiac and vascular pathologies
There is another medical need application of the SUL-compound group with SUL-150, a compound closely related to SUL-238. Recently, a new scientific paper has been published in The International Journal of Molecular Sciences about the potential of...
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases
SUL-238, a first-in-class medicine, protects from ageing
We are happy to share great news! SUL-238 is currently in Phase I clinical trials in collaboration with our Turkish partner GEN Ilac. It is the first drug reported that leads to persisting improvement of vascular aging. This work has recently been...